Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses how nanotechnology can potentially enhance the treatment and delivery of clomiphene citrate for ovulatory disorders, with a focus on improving solubility and minimizing side effects in women experiencing anovulatory infertility, highlighting its 80% efficacy in triggering ovulation in treated cases.

This study compared letrozole and clomiphene citrate for ovulation induction in women with polycystic ovary syndrome and found that while clomiphene led to more follicles, monofollicular development and endometrial thickness were higher with letrozole, and pregnancy rates did not significantly differ between the two treatments.

In this case study, a 62-year-old woman with severe hyperandrogenism underwent a clomiphene test, which suggested an ovarian origin for her condition, leading to the discovery of a Leydig cell tumor after a bilateral oophorectomy.

This case report suggests that clomiphene citrate can effectively restore fertility in some men with a long history of anabolic steroid abuse, though individual responses to treatment vary.

This case report documents the first use of clomiphene citrate to potentially improve fertility in a man taking finasteride, highlighting sperm count issues associated with the medication.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This study found that both Clomiphene Citrate and Human Chorionic Gonadotropin were effective in restoring testosterone levels in men with hypogonadism, as demonstrated in a short-course randomized study.

In this study, researchers investigated factors predicting resistance to clomiphene citrate in women with anovulatory PCOS, identifying AMH and SHBG levels as significant indicators, but they found no reliable thresholds for predicting resistance to the standard 50 mg/day dose.

This study found that combining metformin and clomifene citrate improved pregnancy outcomes and reduced miscarriage rates in women with PCOS and infertility undergoing intrauterine insemination.

In this case study, clomiphene citrate therapy restored hormonal balance and improved symptoms in a young male runner with hypogonadotropic hypogonadism related to endurance exercise.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

This article reviews infertility diagnosis and initial management for advanced practice clinicians, emphasizing the role of midwives and advanced practice nurses, but reports no new clinical findings.

This study observed that the size of vaginal prolapse in patients was significantly related to both the preoperative vaginal length and the length of vaginal excision during the Michigan four-wall sacrospinous suspension procedure.

This study found that vitamin D supplementation significantly improved ovulation rates in PCOS patients undergoing treatment with clomiphene citrate.

This study proposes that combining trazodone and clomiphene citrate could potentially restore libido synaptic circuits and treat post-finasteride syndrome, which involves persistent sexual dysfunction after discontinuing finasteride treatment.

New treatments for male hypogonadism are effective and should be personalized.

This article reviews the coordination of the hypothalamic-pituitary-gonadal axis, male fertility, and therapies for hypogonadism, but reports no new clinical findings.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

This chapter discusses the current developments in Traditional Chinese Medicine for treating PCOS but reports no new clinical results, emphasizing the need for further research in this area.

This book discusses current research on polycystic ovary syndrome, including diagnosis, management, and the impact of lifestyle changes, without reporting new clinical results.

This special issue contains abstracts from the ASA 40th Annual Meeting, providing an overview of various studies without reporting new primary results.

This article discusses diagnostic guidelines for PCOS, emphasizing the use of the Rotterdam criteria and recommending clomiphene citrate as the first-line treatment for ovulation induction; it reports no new clinical results.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This review describes therapeutic strategies for polycystic ovary syndrome, highlighting current treatments for ovulation induction and emphasizing lifestyle changes and personalized approaches, but reports no new clinical results.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This study found that antiandrogenic pretreatment with combined oral contraceptives did not improve ovulation and pregnancy outcomes compared to direct letrozole induction in women with PCOS.

This study concluded that combining letrozole with cabergoline improved ovulation and clinical pregnancy rates in patients with polycystic ovarian syndrome and hyperprolactinemia compared to letrozole alone.

This study suggests that weight loss can improve fertility outcomes in overweight and obese women with PCOS, and letrozole should be considered the new first-line treatment over clomiphene citrate for anovulatory infertility in this population.